Pranela Rameshwar

US Patent:

7119071, Oct 10, 2006

Filed:

May 21, 2002

Appl. No.:

10/154332

Inventors:

Pranela Rameshwar - Maplewood NJ, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

International Classification:

A61K 38/07
C07K 5/10

US Classification:

514 18, 530330

Abstract:

The present invention establishes the fact that the degradation of SP to SP(1-4) by endogenous NEP in BM stroma can be a mediator of hematopoietic stimulation by stem cell factor (SCF) and induce the production of TGF-β and TNF-α in BM stroma. The present invention establishes that compositions containing the SP(1-4) polypeptide, or NEP genetic elements, can be used to slow and or stop the rapid growth of stem and progenitor cells thus protecting them from the deleterious effects of cancer therapy. Hence, the polynucleotides and proteins of the present invention may be used to protect stem cells from the toxic effects of chemo- and radio-therapy, in those undergoing, or about to undergo such cancer related treatments. Also provided are compositions containing NEP antisense sequences and antibodies used for the increased proliferation and differentiation of stem and/or progenitor cells in those whom have already undergone chemo- and/or radio-therapy.

US Patent:

7341867, Mar 11, 2008

Filed:

Jul 25, 2003

Appl. No.:

10/628066

Inventors:

Pranela Rameshwar - Maplewood NJ, US
Pedro Gascon - Barcelona, ES

Assignee:

University of Medicine & Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12N 15/63

US Classification:

4353201, 536 241, 435325

Abstract:

Compositions and methods are provided for identifying novel therapeutic agents for the treatment of breast cancer, bone marrow metastasis, pain, arthritis, aggressive behavior, depression, and certain hematopoietic disorders. Disclosed are promoters and 3′ regulatory regions of genes whose expression differs in malignant cells as compared with non-malignant cells. These include PPT-I, NK-2 and SP-R.

US Patent:

7807462, Oct 5, 2010

Filed:

Nov 15, 2005

Appl. No.:

11/274004

Inventors:

Pranela Rameshwar - Maplewood NJ, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12N 5/08
C12N 5/00

US Classification:

435368, 435325

Abstract:

The present invention relates to the production of functional neurons from adult human mesenchymal stem cells using a retinoid. A retinoid, when used in the absence of a growth factor, transdifferentiates mesenchymal stem cells into functional neurons that exhibit synaptic transmission. Moreover, polarization of the functional neurons can be achieved using selected growth factors. Functional neurons produced in accordance with the method of the invention find use in the treatment or amelioration of diseases or conditions associated with neurodegeneration or nerve damage.

US Patent:

8383806, Feb 26, 2013

Filed:

Apr 13, 2011

Appl. No.:

13/085612

Inventors:

Pranela Rameshwar - Maplewood NJ, US

Assignee:

University of Medicine and Dentistry of New Jersey - Somerset NJ

International Classification:

C07H 21/02
A61K 39/00

US Classification:

536 245, 536 231, 4241981

Abstract:

The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells.

US Patent:

20020146810, Oct 10, 2002

Filed:

Dec 23, 2000

Appl. No.:

09/747429

Inventors:

Pranela Rameshwar - Maplewood NJ, US
Pedro Gascon - Barcelona, ES

International Classification:

C07H021/02
C07H021/04
C12N001/20

US Classification:

435/252300, 536/023100

Abstract:

Compositions and methods are provided for identifying novel therapeutic agents for the treatment of breast cancer, bone marrow metastasis, pain, arthritis, aggressive behavior, depression, and certain hematopoietic disorders. Disclosed are promoters and 3′ regulatory regions of genes whose expression differs in malignant cells as compared with non-malignant cells. These include PPT-I, NK-2 and SP-R.

US Patent:

20020168653, Nov 14, 2002

Filed:

Oct 20, 2001

Appl. No.:

10/039272

Inventors:

Pranela Rameshwar - Maplewood NJ, US

Assignee:

University of Medicine & Dentistry of New Jersey

International Classification:

C12Q001/68
C07H021/04
C12P021/02
C12N005/06
C07K014/705

US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

Bone marrow (BM) is the major organ where immune cells are derived. Homeostasis in the BM is maintained by inter- and intra-cellular interactions by the various subsets of BM cells. The present invention discloses the cloning of a new cDNA from stimulated BM stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The cloned cDNA was designated ‘Hematopoietic Growth Factor Inducible Neurokinin-1 type’ (HGFIN) gene based on its expression in differentiated hematopoietic cells. Hence, the present invention provides a novel gene, HGFIN, which encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. The protein of the present invention may be involved as a central mediator of white blood cell, progenitor, differentiation, and therefore, may be useful in the prevention and treatment of lymphoproliferative syndromes such as B-cell related maladies, including but not limited to acute and chronic myeloid and lymphocytic leukemia as well as the B-cell subtype of Hodgkin's and non-Hodgkin's lymphomas.

US Patent:

20030202938, Oct 30, 2003

Filed:

Jun 17, 2003

Appl. No.:

10/463106

Inventors:

Pranela Rameshwar - Maplewood NJ, US

International Classification:

A61K051/00
A61K039/395

US Classification:

424/001490, 424/145100

Abstract:

The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated BM stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly cancer, because it acts to suppress the proliferating cells.

US Patent:

20060234374, Oct 19, 2006

Filed:

Apr 12, 2006

Appl. No.:

11/279420

Inventors:

Pranela Rameshwar - Maplewood NJ, US

International Classification:

C12N 5/00
C12N 5/02

US Classification:

435325000

Abstract:

The present invention is a method for selecting an enriched population of malignant cells. It has been found that by depleting fibroblasts from a population of cells obtained from a tissue sample; selecting epithelial cells from the fibroblast-depleted population; and culturing the selected epithelial cell population in the presence of bone marrow stromal cells, an enriched population of malignant cells can be selected. In particular, when the malignant cells are constructively passaged on the bone marrow stromal cells, anchorage-independent cells can be obtained. Advantageously, the instant method provides malignant cells which exhibit a preference for bone marrow stromal cells.